Treosulfan - Generic Drug Details

What are the generic sources for treosulfan and what is the scope of freedom to operate?

Treosulfan is the generic ingredient in one branded drug marketed by Medexus and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Treosulfan has twenty-six patent family members in fifteen countries.

There is one drug master file entry for treosulfan. One supplier is listed for this compound.

Summary for treosulfan

International Patents:	26
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	48
Patent Applications:	4,473
What excipients (inactive ingredients) are in treosulfan?	treosulfan excipients list
DailyMed Link:	treosulfan at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for treosulfan

Constraining patent/regulatory exclusivity:

AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH ACUTE MYELOID LEUKEMIA (AML)

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for treosulfan

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital Tuebingen	PHASE2
Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation	PHASE2
Russian Children's Clinical Hospital of the N.I. Pirogov Russian National Research Medical University	PHASE2

See all treosulfan clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for treosulfan

L01AB	Alkyl sulfonates
L01A	ALKYLATING AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for treosulfan

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medexus	GRAFAPEX	treosulfan	POWDER;INTRAVENOUS	214759-002	Jan 21, 2025		RX	Yes	Yes
Medexus	GRAFAPEX	treosulfan	POWDER;INTRAVENOUS	214759-001	Jan 21, 2025		RX	Yes	Yes
Medexus	GRAFAPEX	treosulfan	POWDER;INTRAVENOUS	214759-002	Jan 21, 2025		RX	Yes	Yes
Medexus	GRAFAPEX	treosulfan	POWDER;INTRAVENOUS	214759-001	Jan 21, 2025		RX	Yes	Yes
Medexus	GRAFAPEX	treosulfan	POWDER;INTRAVENOUS	214759-001	Jan 21, 2025		RX	Yes	Yes
Medexus	GRAFAPEX	treosulfan	POWDER;INTRAVENOUS	214759-002	Jan 21, 2025		RX	Yes	Yes

International Patents for treosulfan

Country	Patent Number	Title	Estimated Expiration
Austria	E251455
Australia	1391801	Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation
Australia	777527
Bulgaria	106772	ПРИЛОЖЕНИЕ НА ТРЕОСУЛФАН ЗА ПОДДЪРЖАНЕ СЪСТОЯНИЕТО НА ПАЦИЕНТИ ПРЕДИ ТРАНСПЛАНТАЦИЯ НА КОСТЕН МОЗЪКИЛИ КРЪВНИ СТВОЛОВИ КЛЕТКИ (USE OF TREOSULFAN FOR PATIENT CONDITIONING BEFORE BONE MARROW OR BLOOD STEM CELL TRANSPLANTATION)
Bulgaria	65845
Canada	2389896	UTILISATION DE TREOSULFANE POUR LE CONDITIONNEMENT DE PATIENTS AVANT UNE GREFFE DE MOELLE OSSEUSE OU UNE GREFFE DE CELLULES SANGUINES SOUCHES (USE OF TREOSULFAN FOR PATIENT CONDITIONING BEFORE BONE MARROW OR BLOOD STEM CELL TRANSPLANTATION)
Czech Republic	20021562	Pouľití treosulfanu jako prostředku upravujícího předoperační stav pacienta před transplantací kostní dřeně nebo transplantací krevních kmenových buněk (Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation)

Supplementary Protection Certificates for treosulfan

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1227808	132019000000108	Italy		PRODUCT NAME: TREOSULFAN(TRECONDI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1351, 20190624
1227808	1990039-8	Sweden		PRODUCT NAME: TREOSULFAN; REG. NO/DATE: EU/1/18/1351 20190624
1227808	SPC/GB19/052	United Kingdom		PRODUCT NAME: TREOSULFAN; REGISTERED: UK EU/1/18/1351 20190624
1227808	122019000073	Germany		PRODUCT NAME: TREOSULFAN; REGISTRATION NO/DATE: EU/1/18/1351 20190620
1227808	301002	Netherlands		PRODUCT NAME: TREOSULFAN; REGISTRATION NO/DATE: EU/1/18/1351 20190620
1227808	C201930050	Spain		PRODUCT NAME: TREOSULFANO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1351; DATE OF AUTHORISATION: 20190620; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1351; DATE OF FIRST AUTHORISATION IN EEA: 20190620

TREOSULFAN Market Dynamics and Financial Trajectory: Uptake Drivers, Pricing Pressure, and Exclusivity Risk

Last updated: June 19, 2026

Treosulfan is a cytotoxic prodrug of alkylating agent dienesulfonate used in hematology, most notably in conditioning regimens for hematopoietic stem cell transplantation (HSCT). Commercial momentum is constrained by narrow indication profiles, intensive chemotherapy competition, limited reimbursement footprints in some markets, and the absence (to date) of large, label-expanding blockbuster dynamics. Financial trajectory is therefore primarily shaped by transplant volumes, conditioning regimen selection, payer acceptance, and channel access, with exclusivity and patent estate timing driving generic and biosimilar substitution risk where applicable.

What is treosulfan and what is its commercial role in HSCT conditioning?

Treosulfan is used as part of conditioning chemotherapy for HSCT. Its market role is typically as one regimen component rather than a standalone chronic therapy category.

Indication shape: transplant-centric demand

• Demand is driven by:
  • HSCT procedure volumes (adult and pediatric).
  • Choice of conditioning regimen (treosulfan-based vs busulfan-based vs other alkylator strategies).
  • Center prescribing preferences and local protocols.
• Demand is not driven by long-duration outpatient use, so seasonality and adherence economics are limited.

Delivery format and regimen economics

Treosulfan is generally deployed in multi-day inpatient conditioning protocols, which makes:

• Hospital acquisition strategy and pharmacy tendering central.
• Bundled inpatient reimbursement and hospital procurement policies key determinants of realized pricing.

How do HSCT transplant volumes influence treosulfan revenue growth?

HSCT volumes are the primary top-down driver for treosulfan’s revenue ceiling. Treosulfan utilization depends on how often clinicians select treosulfan conditioning relative to alternatives.

Procedure volume and mix effects

• Higher transplant volumes increase potential eligible patients.
• Patient mix shifts (age distribution, comorbidities, transplant type) can change regimen selection.
• Uptake is typically uneven across geographies due to:
  • guideline adoption speed,
  • formulary structure,
  • and procurement lead times at transplant centers.

Center-level utilization dynamics

• Once a major transplant center standardizes on conditioning regimens, switching costs stay high:
  • protocol validation,
  • nursing and pharmacy operational fit,
  • and historical outcomes monitoring.
• New entrants in the product market can grow faster where protocols are still evolving.

What pricing and reimbursement dynamics affect treosulfan financially?

Treosulfan operates in a high-acuity chemotherapy environment where pricing is strongly influenced by payer and hospital procurement mechanisms.

Pricing pressure channels

• Reference pricing and tendering:
  • In multiple European systems and hospital-driven markets, purchasing tenders and budget impact determine net pricing.
• Limited alternative substitutability:
  • If treosulfan is the only conditioning option that aligns with protocol constraints for certain patient groups, payer pressure may ease.
  • If competing conditioning chemotherapies are interchangeable at guideline level, pricing pressure strengthens.

Net price vs list price reality

• The commercial outcome is typically measured by:
  • contract prices with distributors,
  • hospital tender awards,
  • and reimbursement status category in each country.
• Without label expansion into high-volume outpatient settings, revenue elasticity to price can be limited, but procurement pressure still caps realized margin.

What patents protect treosulfan and how does exclusivity affect market timing?

Treosulfan is an older, established active substance. The economic implication is that market exclusivity and patent estate status determine whether supply can be challenged with generic competition and whether branded differentiation persists.

Typical patent buckets relevant to specialty cytotoxics

• Composition of matter (active ingredient derivatives, prodrug claims).
• Formulation patents (stability, solubilization, container/packaging).
• Manufacturing process patents.
• Use patents (specific conditioning regimens, patient subgroups, dosing schedules).

Exclusivity and generic risk framework

For a hospital chemotherapy product, the dominant generic-entry path is usually through:

• FDA/EMA marketing authorization of a generic (where allowed by local frameworks),
• followed by tender-driven substitution.

The timing of generic competition is therefore often more sensitive to:

• regulatory authorization date in each jurisdiction,
• than to marketing timelines alone.

What is the FDA status and Orange Book status of treosulfan products?

A complete FDA regulatory and Orange Book status mapping requires product-level verification because treosulfan may be marketed under different brand names and strengths, and because multiple NDA/ANDA lines may exist. Without that product-by-product mapping, an accurate status statement cannot be produced.

Which companies market treosulfan and what is the competitive landscape?

Treosulfan’s competitive landscape depends on the number of authorized products by geography and whether competing manufacturers have achieved:

• tender eligibility,
• hospital formulary acceptance,
• and reliable supply.

Competitive dynamics in hospital procurement

In specialty oncology and transplant conditioning markets, competition is shaped by:

• supply reliability and lead times,
• ability to support bulk procurement contracts,
• and distribution coverage to transplant centers.

How strong is the patent estate for treosulfan versus conditioning alternatives like busulfan?

Treosulfan competes economically within conditioning chemotherapy choices, especially regimens that aim to balance:

• efficacy,
• toxicity profiles,
• and logistical feasibility for transplant centers.

Economic substitution pressure

If busulfan-based protocols or other conditioning chemotherapies are considered clinically interchangeable for certain patient profiles, treosulfan faces:

• margin compression after generic entry,
• and limited pricing power even in branded periods.

If treosulfan has clear protocol adoption in specific transplant settings, it can preserve a more stable share, but it does not remove:

• tender-driven pressure,
• and supply competition risk.

What patent litigation or Paragraph IV challenges affect treosulfan?

Patent litigation and Paragraph IV challenges are product- and jurisdiction-specific. Without a verified litigation docket tied to named treosulfan products and assignees, producing a complete litigation-impact profile would be incomplete.

What formulations are protected by patents and how does that shape generic barriers?

In cytotoxic formulations, generic barriers often concentrate in:

• stability-enhancing excipients,
• concentration and pH characteristics,
• container-closure compatibility,
• and manufacturing process controls that affect shelf-life and sterility assurance.

Generic entry becomes harder when:

• formulation-specific claims exist,
• stability data are tied to regulatory approval,
• and multiple patents span composition, process, and use.

When does treosulfan lose exclusivity in major markets and what launch scenarios follow?

Exclusivity loss timing depends on:

• product-specific regulatory approvals,
• marketing authorization pathways,
• and patent expiration schedules by jurisdiction.

Without product-level verification of treosulfan’s marketed authorizations and their linked patent sets, an exclusivity timeline by year or by geography cannot be accurately stated.

What is the financial trajectory: growth, margin, and cashflow patterns for treosulfan?

Treosulfan’s financial trajectory is best understood through transplant-linked revenue and procurement economics rather than blockbuster scaling.

Revenue growth profile (typical specialty pattern)

• Base demand grows with:
  • transplant volume trends,
  • center protocol adoption,
  • and replacement of older regimens.
• Volume growth is usually capped by:
  • guideline saturation,
  • regional practice variation,
  • and changes in conditioning standards.

Margin compression risks

• When generic competition arrives, margins typically compress quickly because:
  • procurement tends to shift to lowest-cost supply that meets specifications,
  • oncology drugs are often bought under contract frameworks.

Cashflow timing

• Working capital intensity depends on:
  • inventory strategies for hospital demand,
  • cold-chain logistics if relevant,
  • and reimbursement cycle timing.

How do payer decisions and procurement tenders change treosulfan’s net price over time?

Net pricing is usually the decisive metric for specialty hospital oncology drugs. Over time, the following patterns are common:

• Early period: higher net price during branded exclusivity and limited sourcing.
• Middle period: incremental price concessions tied to tender re-awards.
• Late period: larger declines when generic or alternative branded supplies gain tender eligibility.

Key Takeaways

• Treosulfan’s market dynamics are transplant-centric, so revenue is primarily driven by HSCT volume trends and regimen selection.
• Pricing pressure is hospital procurement-driven, with net price moving more than list price through tenders and contract re-awards.
• Financial trajectory is constrained by limited label expansion potential typical of conditioning chemotherapy products.
• Generic and exclusivity risks are the main timeline determinants, but a verified patent and regulatory status map by product and geography is required for year-accurate exclusivity and launch scenarios.

FAQs

1. What factors determine treosulfan conditioning regimen uptake at transplant centers?
   Protocol guidelines, patient eligibility, historical outcomes, and hospital pharmacy operational fit.

2. How does tendering typically impact specialty cytotoxic drug net pricing after generic entry?
   Contract re-awards shift purchasing toward lowest-cost authorized supply, driving margin compression.

3. What are the main revenue risks for treosulfan compared with broader oncology drugs?
   Narrow indication volume, transplant practice variation, and faster procurement-driven substitution.

4. Do formulation differences materially affect generic substitution of cytotoxic conditioning drugs?
   Yes, formulation stability, concentration specs, and manufacturing controls can create regulatory and IP barriers.

5. What commercial KPIs best track treosulfan performance over time?
   Net contract price, tender win rate, hospital formulary penetration, and HSCT protocol share.

References (APA)

1. (No cited sources available in the provided context.)